A year after British pharmaceutical giant, GlaxoSmithKline exited Nigeria and asthmatic patients who depended on its inhalers faced significant distress due to the medication’s scarcity ...

or GSK, after promising to cap the out-of-pocket cost of inhalers at $35. Instead, GSK shifted production to another company through a licensing agreement, avoiding required payments to Medicaid ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

GlaxoSmithKline is recalling more than 593,000 asthma inhalers in the US due to a defect that may cause them to deliver fewer doses of the medicine than indicated. The company said it would be ...

Both inhalers provide the advantage of once-daily ... paid by CMS for comparator drugs remain undisclosed. Price Action: GSK stock is up 2.55% at $38.92 at the last check Tuesday.

Elizabeth Warren (D-Mass.) is asking a federal watchdog to investigate GSK for replacing a popular asthma inhaler with a so-called authorized generic at a much higher price in order to avoid ...

The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of oral antibiotics for the condition in nearly 30 years. Blujepa, also ...

has approved a new drug for treating urinary tract infections (UTIs), the first such drug approved in decades and the first in a new class of medications. British pharmaceutical company GSK ...